Comirnaty (tozinameran - Pfizer/BIONTECH) in COVID-19 prophylaxis (children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias confirmed Covid-19, from 1st dosedetailed results C4591001 (Adolescents 12-25), 2021 0.08 [0.02; 0.34]
June, 2021 0.09 [0.08; 0.10]
0.09 [0.08 ; 0.10 ] C4591001 (Adolescents 12-25), 2021, June, 2021 2 0% 1,304,680 NA not evaluable confirmed COVID (any severity)detailed results Glatman-Freedman A, 2021 0.09 [0.06; 0.12]
June, 2021 0.01 [0.00; 0.05]
Lutrick (PROTECT study), 2021 0.08 [0.03; 0.21]
Reis, 2021 0.10 [0.08; 0.12]
Tartof, 2021 0.09 [0.07; 0.12]
Veneti, 2022 0.09 [0.07; 0.13]
Walter E.B. (Children <12 Years of Age), 2021 0.09 [0.03; 0.32]
0.09 [0.08 ; 0.11 ] Glatman-Freedman A, 2021, June, 2021, Lutrick (PROTECT study), 2021, Reis, 2021, Tartof, 2021, Veneti, 2022, Walter E.B. (Children <12 Years of Age), 2021 7 26% 1,304,606 NA serious hospitalizationdetailed results Klein ( VISION network), 2022 0.26 [0.05; 1.35]
Olson (July to October), 2022 0.05 [0.03; 0.09]
Olson (June to September), 2021 0.09 [0.03; 0.26]
Price, 2022 0.17 [0.12; 0.24]
Tartof, 2021 0.19 [0.02; 1.67]
0.11 [0.06 ; 0.23 ] Klein ( VISION network), 2022, Olson (July to October), 2022, Olson (June to September), 2021, Price, 2022, Tartof, 2021 5 70% NA not evaluable symptomatic Covid-19detailed results C4591001 (Adolescents 12-25), 2021 0.03 [0.00; 0.50]
Klein ( VISION network), 2022 0.54 [0.43; 0.67]
Reis, 2021 0.07 [0.04; 0.14]
0.14 [0.02 ; 0.82 ] C4591001 (Adolescents 12-25), 2021, Klein ( VISION network), 2022, Reis, 2021 3 94% 1,983 NA not evaluable ICU admissiondetailed results Olson (July to October), 2022 0.02 [0.01; 0.05]
0.02 [0.01 ; 0.05 ] Olson (July to October), 2022 1 0% NA not evaluable infection (PCR positive symptomatic or not)detailed results June, 2021 99.10 [98.60; 99.60]
99.10 [98.60 ; 99.60 ] June, 2021 1 0% NA not evaluable severe COVID-19 occurrencedetailed results Price, 2022 0.04 [0.02; 0.09]
0.04 [0.02 ; 0.09 ] Price, 2022 1 0% NA not evaluable vaccine efficacy after dose 1 (and before dose 2)detailed results C4591001 (Adolescents 12-25), 2021 0.25 [0.05; 1.13]
June, 2021 91.10 [89.66; 92.56]
5.01 [0.02 ; 1627.08 ] C4591001 (Adolescents 12-25), 2021, June, 2021 2 98% 2,239 low not evaluable 0.0 200.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-02 06:31 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
